Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

The employee equity awards carry four-year vesting schedules, with vesting subject to continued service.

Rhea-AI Summary

Mineralys Therapeutics (Nasdaq: MLYS) granted stock options and restricted stock units to a new non-executive employee on November 3, 2026.

The awards cover 14,880 option shares and 11,160 restricted stock units under the 2025 Employment Inducement Incentive Award Plan. Both awards vest over four years, subject to continued service, with a vesting commencement date of November 2, 2026. The grants were employment inducements made in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 14,880 shares create potential dilution as the employee award vests and is exercised.
• Minor point. Forward-looking: it has not happened yet and may not happen.Restricted stock units covering 11,160 shares create potential dilution as the employee award vests.

Key Figures

Inducement stock option award: 14,880 shares Inducement restricted stock unit award: 11,160 shares Option vesting schedule: Four years; 25% at the first anniversary, then 1/48 monthly +1 more

Inducement stock option award

14,880 shares

Granted to a new non-executive employee

Inducement restricted stock unit award

11,160 shares

Granted to a new non-executive employee

Option vesting schedule

Four years; 25% at the first anniversary, then 1/48 monthly

Subject to continued service

Restricted stock unit vesting schedule

Four years; 25% on each of the first four anniversaries

Subject to continued service

Key Terms

restricted stock unit, vesting commencement date, nasdaq listing rule 5635(c)(4)

3 terms

restricted stock unit financial

"an inducement restricted stock unit award covering 11,160 shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

vesting commencement date financial

"the first anniversary of the award’s vesting commencement date"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RADNOR, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on November 3, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 14,880 shares and an inducement restricted stock unit award covering 11,160 shares of Mineralys common stock to a new non-executive employee.

The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option award will vest over a four-year period, with 25% of the total shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, November 2, 2026, and 1/48th of the total shares underlying the award vesting following each one-month period thereafter, subject to continued service. The restricted stock unit award will vest over a four-year period, with 25% of the shares vesting on each of the first four anniversaries of the award’s vesting commencement date, November 2, 2026, subject to continued service. The awards were granted as an inducement material to the new non-executive employee entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Contact:

Investor Relations

investorrelations@mineralystx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement awards did Mineralys Therapeutics grant on November 3, 2026?

Mineralys granted a new non-executive employee options covering 14,880 shares and restricted stock units covering 11,160 shares. The awards were granted under its 2025 Employment Inducement Incentive Award Plan as inducements to enter employment.

How do Mineralys Therapeutics' November 2026 employee inducement awards vest?

Both awards vest over four years from a November 2, 2026 vesting commencement date, subject to continued service. Options vest 25% on the first anniversary, then 1/48th of the total underlying shares following each one-month period thereafter. Restricted stock units vest 25% on each of the first four anniversaries.